<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 22, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372602</url>
  </required_header>
  <id_info>
    <org_study_id>202007009</org_study_id>
    <nct_id>NCT04372602</nct_id>
  </id_info>
  <brief_title>Duvelisib to Combat COVID-19</brief_title>
  <official_title>A Pilot Study of Duvelisib to Combat COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The exceedingly high mortality rates of severe and critical COVID-19 warrant the&#xD;
      identification and evaluation of novel therapies that could potentially mitigate the advanced&#xD;
      disease manifestations. Based on preclinical data from this institution and others, the&#xD;
      investigators hypothesize that PI3K inhibition with duvelisib could potentially quell&#xD;
      aberrant hyperactivtation of the innate immune system, preferentially polarize macrophages,&#xD;
      reduce pulmonary inflammation, and limit viral persistence, thereby improving patient&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blocks of 10 patients will be used to allocate patients to duvelisib or placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Through completion of follow-up (estimated to be 7 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>Through completion of follow-up (estimated to be 7 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilator use</measure>
    <time_frame>Through completion of follow-up (estimated to be 7 months)</time_frame>
    <description>-For those on a ventilator at the time of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of vasopressors use</measure>
    <time_frame>Through completion of follow-up (estimated to be 7 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration on renal replacement therapy</measure>
    <time_frame>Through completion of follow-up (estimated to be 7 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral kinetics as measured by virologic failure</measure>
    <time_frame>Through completion of follow-up (estimated to be 7 months)</time_frame>
    <description>-Defined as increase in viral load of &gt;0.5 log on two consecutive days, or &gt;1 log increase in one day, not in keeping with any baseline trend of rising viral loads during the pre-treatment viral testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events as measured by CTCAE v. 5.0</measure>
    <time_frame>Through completion of follow-up (estimated to be 7 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Duvelisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Duvelisib 25 mg twice daily for up to 10 days. Patients who have significant clinical improvement prior to day 10 and are going to be discharged from the hospital may discontinue the treatment early with investigator permission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>-Placebo 25 mg twice daily for up to 10 days. Patients who have significant clinical improvement prior to day 10 and are going to be discharged from the hospital may discontinue the treatment early with investigator permission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.</description>
    <arm_group_label>Duvelisib</arm_group_label>
    <other_name>Copiktra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood draw</intervention_name>
    <description>First 10 patients enrolled&#xD;
Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29</description>
    <arm_group_label>Duvelisib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>-Provided by Verastem</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of advanced COVID-19 as defined both of the following:&#xD;
&#xD;
               -  as a positive test for SARS-CoV-2 RNA detected by RT-PCR collected from the upper&#xD;
                  respiratory tract (e.g. nasopharyngeal, nasal, oropharyngeal swab, or saliva)&#xD;
                  and, if possible, the lower respiratory tract (sputum, tracheal aspirate, or&#xD;
                  bronchoalveolar lavage), analyzed by a CLIA certified lab with an FDA approved&#xD;
                  assay.&#xD;
&#xD;
               -  Critical disease manifested by any of the following:&#xD;
&#xD;
                    -  Chest imaging with ≥ 50% lung involvement&#xD;
&#xD;
                    -  Respiratory failure requiring invasive mechanical ventilation, non-invasive&#xD;
                       mechanical ventilation (eg. BiPAPA, OptiFlow), supplementary oxygen with&#xD;
                       FiO2 ≥ 6 LPM or extracorporeal membrane oxygenation (ECMO)&#xD;
&#xD;
                    -  Shock - defined as mean arterial pressure ≤ 65 mmHg unresponsive to 25ml/kg&#xD;
                       isotonic intravenous fluid resuscitation and/or requiring vasopressor&#xD;
                       support&#xD;
&#xD;
                    -  Cardiac dysfunction defined by:&#xD;
&#xD;
                         -  New global systolic dysfunction with ejection fraction ≤ 40%&#xD;
&#xD;
                         -  Takotsubo cardiomyopathy&#xD;
&#xD;
          -  Patients who have received prior investigational or off-label agents for COVID-19 does&#xD;
             not exclude eligibility.&#xD;
&#xD;
          -  At least 18 years of age at the time of study registration&#xD;
&#xD;
          -  Adequate hematologic function defined as absolute neutrophil count ≥1000/mm3 and&#xD;
             platelet count ≥ 50,000/mm3 without growth factor or transfusion support for 7 days&#xD;
             prior to screening.&#xD;
&#xD;
          -  Creatinine-clearance ≥ 15 mL/minute or receiving renal replacement therapy&#xD;
&#xD;
          -  Aminotransferase (AST/ALT) levels &lt;3x the upper limit of normal&#xD;
&#xD;
          -  Able to understand and willing to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable)&#xD;
&#xD;
          -  Women of childbearing potential (defined as women with regular menses, women with&#xD;
             amenorrhea, women with irregular cycles, women using a contraceptive method that&#xD;
             precludes withdrawal bleeding, or women who have had a tubal ligation) are required to&#xD;
             have a negative pregnancy test and use two forms of acceptable contraception,&#xD;
             including one barrier method, during participation in the study treatment period.&#xD;
&#xD;
          -  Male patients if engaging in sex with a women of childbearing potential are required&#xD;
             to use two forms of acceptable contraception, including one barrier method, during&#xD;
             participation in the study and throughout the evaluation period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or intolerance to duvelisib or another PI3K inhibitor.&#xD;
&#xD;
          -  Known or suspected active viral (including CMV, HIV, hepatitis B, and hepatitis C),&#xD;
             bacterial, mycobacterial, or fungal infection other than COVID-19. CMV viral load will&#xD;
             be assessed at screening and those with viremia will be excluded. Other virologic&#xD;
             testing not required unless infection is suspected.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding.&#xD;
&#xD;
          -  Any uncontrolled intercurrent illness that would put the patient at greater risk or&#xD;
             limit compliance with study requirements in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John DiPersio, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John DiPersio, M.D., Ph.D.</last_name>
    <phone>314-454-8491</phone>
    <email>jdipersi@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erik Dubberke, M.D., MSPH</last_name>
    <phone>314-454-8293</phone>
    <email>edubberk@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nitin Anand, M.D.</last_name>
      <email>nitin.anand@bjc.org</email>
    </contact>
    <investigator>
      <last_name>Nitin Anand, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John DiPersio, M.D., Ph.D.</last_name>
      <phone>314-454-8491</phone>
      <email>jdipersi@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erik Dubberke, M.D., MSPH</last_name>
      <phone>314-454-8293</phone>
      <email>edubberk@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John DiPersio, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Dubberke, M.D., MSPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Fiala, MSW</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>